Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Syros Pharmaceuticals (SYRS) today. The company’s shares opened today at $9.15.
According to TipRanks.com, Breidenbach is a 3-star analyst with an average return of 2.0% and a 40.9% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Alpine Immune Sciences Inc, and Global Blood Therapeutics.
Currently, the analyst consensus on Syros Pharmaceuticals is a Strong Buy with an average price target of $13.75, which is a 50.3% upside from current levels. In a report issued on March 8, JMP Securities also initiated coverage with a Buy rating on the stock with a $18 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.86 and a one-year low of $5.17. Currently, Syros Pharmaceuticals has an average volume of 157.6K.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations.
